The global pharmaceutical industry generated more than $1.25tr in revenue in 2019, up from $1.2tr in 2018, and the final figures for 2020 are expected to be even more impressive. In such a fast-paced environment, pharmaceutical companies need to do all they can to ensure their products, no matter whether they are new innovations or improvements to existing active pharmaceutical ingredient (API) solids, stand out in the market. The question facing pharmaceutical companies is: how to? John Mykytiuk at Sterling Pharma Solutions explains that the answer to achieving these all-important enhancements lies in perfecting the physical characteristics of the API solid itself through solid-form development.